Clinical trials: Cardiovascular Risk Factors

Coronary Heart Disease

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

• Completed
• Age: 18 to 75 years
• Phase 2
• Results posted

This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors.

Trial name

NCT00655473

Testing

Dalcetrapib (RO4607381)

Where

12 sites in United States, Canada

Volunteers

130 people

Sponsor

Hoffmann-La Roche